What's Happening?
Ampersand Biomedicines has presented new preclinical data for AMP-220, a gut-targeted IL-22 AND-Body therapeutic, at the AAI 2026 conference. The data demonstrate AMP-220's ability to selectively activate IL-22 in the gut epithelium, providing therapeutic benefits
in inflammatory bowel disease (IBD) models while avoiding off-target toxicities. The therapeutic is designed using Ampersand's AND Platform, which combines a gut-specific targeting moiety with an engineered IL-22 cytokine mutein. Preclinical results show AMP-220's high potency and selectivity, with significant efficacy in IBD models and reduced systemic side effects.
Why It's Important?
AMP-220 represents a significant advancement in the treatment of IBD, a condition that affects millions and often requires long-term management. By targeting IL-22 activity specifically to the gut, AMP-220 offers a more precise and potentially more effective treatment option with fewer side effects. This approach could improve patient outcomes and quality of life, addressing a critical need for safer, more targeted therapies in IBD management. The success of AMP-220 also highlights the potential of Ampersand's AND Platform to develop next-generation biologics for various diseases.
What's Next?
Ampersand Biomedicines is continuing IND-enabling studies for AMP-220, with plans to enter clinical trials next year. The company will focus on further validating the therapeutic's efficacy and safety in human studies. If successful, AMP-220 could become a leading treatment option for IBD, potentially transforming the therapeutic landscape for this condition. Ampersand may also explore additional applications of its AND Platform to develop targeted therapies for other diseases.
